Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

GSKGSK plc

NYSE · CIK 0001131399
Filer categoryLarge accelerated filer
Entity typeother
SIC2834 Pharmaceutical Preparations
FY end—
XBRL facts432

Identity from submissions API

NameGSK plc
CIK0001131399
TickersGSK, GLAXF
ExchangesNYSE, OTC
Entity typeother
CategoryLarge accelerated filer
SIC2834 Pharmaceutical Preparations
EIN000000000
LEI—
Fiscal year end—
State of incorporationX0 United Kingdom
Phone44 20 8047 5000
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)0
Insider transactions (owner)1

Former names

  • GLAXOSMITHKLINE PLC (2001-05-14T00:00:00.000Z → 2022-05-16T00:00:00.000Z)
Business address
79 NEW OXFORD STREET
LONDON
WC1A 1DG
United Kingdom
X0
Mailing address
79 NEW OXFORD STREET
LONDON
WC1A 1DG
United Kingdom
X0

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

6860 filing rows loaded from submissions recent; extra archives: CIK0001131399-submissions-001.json (2002 filings, 2013-10-04 to 2022-08-14); CIK0001131399-submissions-002.json (2001 filings, 2007-09-13 to 2013-10-02); CIK0001131399-submissions-003.json (1856 filings, 2001-01-12 to 2007-09-11).

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-20 6-K TRANSFER OF TREASURY SHARES 0001654954-26-010027 001-15170 261577352 34 22130
2026-11-19 6-K VELZATINIB OBTAINS ODD IN JAPAN FOR GIST TREATMENT 0001654954-26-009980 001-15170 261572320 34 43379
2026-11-18 6-K FDA APPROVES NELKARMI FOR PRETREATED ALK+ NSCLC 0001654954-26-009959 001-15170 261568010 34 47247
2026-11-17 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-009909 001-15170 261564412 34 98275
2026-11-13 6-K BEXSERO BOOSTER RECEIVES POSITIVE CHMP OPINION 0001654954-26-009743 001-15170 261548905 34 44404
2026-11-12 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-009712 001-15170 261544683 34 212934
2026-11-06 6-K GSK PUBLISHES PROVISIONAL DIVIDEND DATES 0001654954-26-009585 001-15170 261529897 34 27404
2026-11-05 13F-HR xslForm13F_X02/primary_doc.xml 0001999371-26-024635 028-26280 261527191 34 9917
2026-11-02 6-K TOTAL VOTING RIGHTS 0001654954-26-009362 001-15170 261510482 34 18710
2026-10-28 6-K 3RD QUARTER RESULTS 0001654954-26-009181 001-15170 261493689 34 1873920
2026-10-26 6-K RIS-REZ POSITIVE PH 3 OSTEOSARCOMA DATA IN CHINA 0001654954-26-009141 001-15170 261484801 34 45620
2026-10-26 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-009139 001-15170 261484775 34 34108
2026-10-26 6-K JEMPERLI DATA SHOW 76% COMPLETE RESPONSE RATE 0001654954-26-009130 001-15170 261483512 34 50352
2026-10-26 6-K POSITIVE MO-REZ PHASE IB DATA IN OVARIAN CANCER 0001654954-26-009127 001-15170 261483474 34 54321
2026-10-21 6-K US FDA APPROVES HIBSAGO FOR CHRONIC HEPATITIS B 0001654954-26-009062 001-15170 261474107 34 53545
2026-10-19 6-K JEMPERLI APPROVED IN MSI-H/DMMR RECTAL CANCER 0001654954-26-009036 001-15170 261468368 34 52310
2026-10-19 6-K RIS-REZ POSITIVE EARLY DATA IN LUNG CANCER 0001654954-26-009023 001-15170 261467505 34 49093
2026-10-15 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-008959 001-15170 261461934 34 74756
2026-10-14 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-008950 001-15170 261459003 34 265422
2026-10-13 S-8 S-8 0001193125-26-420025 333-299423 261455856 33 589512 1 1
2026-10-13 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-008921 001-15170 261455773 34 417513
2026-10-13 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-008889 001-15170 261454469 34 537938
2026-10-08 6-K WENDY BECKER CBE - NEW DIRECTORSHIP 0001654954-26-008854 001-15170 261448924 34 17179
2026-10-06 6-K ADMISSION TO TRADING 0001654954-26-008813 001-15170 261442658 34 30198
2026-10-01 6-K TOTAL VOTING RIGHTS 0001654954-26-008733 001-15170 261429540 34 20499
2026-09-24 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-008553 001-15170 261402967 34 35142
2026-09-22 CERT NYSE CERTIFICATION 0000876661-26-000783 001-15170 261395677 34 159899
2026-09-22 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-008503 001-15170 261395625 34 176795
2026-09-15 8-A12B 8-A12B 0001193125-26-391619 001-15170 261379938 34 383660
2026-09-15 6-K 6-K 0001193125-26-391597 001-15170 261379867 34 203672
2026-09-15 6-K GSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMA 0001654954-26-008359 001-15170 261379046 34 41998
2026-09-14 6-K RIS-REZ POSITIVE PH 3 OS LUNG CANCER DATA IN CHINA 0001654954-26-008321 001-15170 261375798 34 48655
2026-09-14 6-K JIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLC 0001654954-26-008318 001-15170 261375787 34 50022
2026-09-11 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-008280 001-15170 261373049 34 214830
2026-09-10 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-008255 001-15170 261370009 34 36277
2026-09-10 424B2 424B2 0001193125-26-387354 333-278205 261369760 33 758797 1 1
2026-09-10 6-K JAPAN APPROVAL OF SHINGRIX IN A PREFILLED SYRINGE 0001654954-26-008234 001-15170 261369558 34 44948
2026-09-09 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-008205 001-15170 261367129 34 51877
2026-09-09 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-008202 001-15170 261367092 34 40856
2026-09-09 FWP FWP 0001193125-26-385857 333-278205 261366600 34 33598
2026-09-08 424B2 424B2 0001193125-26-384490 333-278205 261363570 33 607528
2026-09-08 6-K 6-K 0001193125-26-384439 001-15170 261363474 34 2262969
2026-09-01 6-K TOTAL VOTING RIGHTS 0001654954-26-008044 001-15170 261349475 34 19937
2026-09-01 6-K MRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE III 0001654954-26-007998 001-15170 261348536 34 46570
2026-08-26 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-007877 001-15170 261318438 34 35203
2026-08-24 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-007810 001-15170 261307212 34 61721
2026-08-24 6-K FIRST GLOBAL APPROVAL FOR HIBSAGO IN JAPAN 0001654954-26-007800 001-15170 261306310 34 57712
2026-08-24 6-K US FDA TO REVIEW JEMPERLI FOR RECTAL CANCER 0001654954-26-007798 001-15170 261306294 34 57701
2026-08-20 144 xsl144X01/primary_doc.xml 0001949846-26-000534 001-15170 261298084 33 7641
2026-08-18 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-007718 001-15170 261288939 34 95976
2026-08-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-349401 005-84251 261274308 34 7385
2026-08-13 13F-HR xslForm13F_X02/primary_doc.xml 0001999371-26-017873 028-26280 261274109 34 9920
2026-08-13 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-007560 001-15170 261271286 34 195949
2026-08-11 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-007453 001-15170 261261376 34 34223
2026-08-03 6-K TOTAL VOTING RIGHTS 0001654954-26-007176 001-15170 261231158 34 20680
2026-07-30 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-007005 001-15170 261221625 34 35885
2026-07-28 6-K NEW GSK FLAGSHIP R&D CENTRE IN CAMBRIDGE 0001654954-26-006954 001-15170 261209987 34 37364
2026-07-28 6-K HANSOH POSITIVE 2ND PHASE III RESULTS FOR RIZ-REZ 0001654954-26-006951 001-15170 261209921 34 43771
2026-07-28 6-K 2ND QUARTER RESULTS 0001654954-26-006949 001-15170 261209805 34 1941025
2026-07-24 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-006862 001-15170 261199629 34 34050
2026-07-24 6-K ADMISSION TO TRADING 0001654954-26-006854 001-15170 261199214 34 30188
2026-07-22 6-K JIDEYTRO APPROVED IN US FOR CERTAIN LUNG CANCERS 0001654954-26-006789 001-15170 261192906 34 51703
2026-07-20 6-K BEXSERO 1-DOSE BOOSTER EMA FILE ACCEPTANCE 0001654954-26-006735 001-15170 261185476 34 39751
2026-07-17 6-K AUDIT TENDER CONCLUSION 0001654954-26-006706 001-15170 261181852 34 19084
2026-07-17 6-K CAMLIPIXANT PHASE III RESULTS UPDATE 0001654954-26-006705 001-15170 261181825 34 36533
2026-07-16 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-006691 001-15170 261179088 34 239414
2026-07-15 6-K GSK COMPLETES ACQUISITION OF NUVALENT, INC 0001654954-26-006663 001-15170 261176106 34 38131
2026-07-15 SC TO-T/A SC TO-T/A 0001193125-26-304122 24074
2026-07-14 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-006640 001-15170 261173107 34 570599
2026-07-13 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-006623 001-15170 261170499 34 434544
2026-07-13 6-K POSITIVE JEMPERLI DATA IN DMMR/MSI-H RECTAL CANCER 0001654954-26-006614 001-15170 261169919 34 51869
2026-07-10 SC TO-T/A SC TO-T/A 0001193125-26-300322 23142
2026-07-10 6-K HANSOH POSITIVE PHASE III RESULTS FOR RIZ-REZ 0001654954-26-006601 001-15170 261167007 34 42128
2026-07-09 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-006560 001-15170 261164658 34 34418
2026-07-09 6-K DIRECTORATE CHANGE 0001654954-26-006557 001-15170 261163967 34 31998
2026-07-07 SC TO-T/A SC TO-T/A 0001193125-26-297562 26958
2026-07-01 6-K TOTAL VOTING RIGHTS 0001654954-26-006424 001-15170 261143092 34 18699
2026-06-29 6-K TRANSACTION IN OWN SHARES 0001654954-26-006273 001-15170 261132317 34 48964
2026-06-29 6-K HOLDING(S) IN COMPANY 0001654954-26-006269 001-15170 261132292 34 66034
2026-06-26 6-K HOLDING(S) IN COMPANY 0001654954-26-006220 001-15170 261124603 34 61388
2026-06-24 SC TO-T/A SC TO-T/A 0001193125-26-281024 61972
2026-06-24 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-006170 001-15170 261114194 34 35392
2026-06-24 6-K GSK ANNOUNCES TENDER OFFER TO ACQUIRE NUVALENT 0001654954-26-006168 001-15170 261114018 34 61313
2026-06-24 SC TO-T SC TO-T 0001193125-26-280246 2485409 1 1
2026-06-23 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-006116 001-15170 261109648 34 158462
2026-06-22 6-K TRANSACTION IN OWN SHARES 0001654954-26-006106 001-15170 261105480 34 46622
2026-06-17 11-K 11-K 0001628280-26-043782 001-15170 261097253 34 3295340 1 1
2026-06-17 11-K 11-K 0001628280-26-043773 001-15170 261097170 34 4517849 1 1
2026-06-17 6-K CUTI ORAL ANTIBIOTIC TEBIPENEM APPROVED BY US FDA 0001654954-26-006036 001-15170 261097163 34 60037
2026-06-15 6-K TRANSACTION IN OWN SHARES 0001654954-26-005975 001-15170 261089307 34 46867
2026-06-12 6-K MOMELOTINIB ORPHAN DRUG DESIGNATIONS FOR VEXAS 0001654954-26-005913 001-15170 261084870 34 51369
2026-06-11 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-005880 001-15170 261081786 34 203609
2026-06-10 SC TO-C SC TO-C 0001193125-26-265991 649263
2026-06-10 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-005844 001-15170 261078578 34 34042
2026-06-09 SC TO-C SC TO-C 0001193125-26-264048 10139241
2026-06-09 6-K DR HAL BARRON - NEW DIRECTORSHIP 0001654954-26-005819 001-15170 261075467 34 19669
2026-06-09 SC TO-C SC TO-C 0001193125-26-262957 73550
2026-06-09 6-K GSK ENTERS AGREEMENT TO ACQUIRE NUVALENT, INC. 0001654954-26-005800 001-15170 261074523 34 64548
2026-06-08 6-K TRANSACTION IN OWN SHARES 0001654954-26-005771 001-15170 261072675 34 47362
2026-06-01 6-K TOTAL VOTING RIGHTS 0001654954-26-005589 001-15170 261048005 34 19647
2026-06-01 6-K TRANSACTION IN OWN SHARES 0001654954-26-005584 001-15170 261047807 34 44773
2026-05-28 6-K POSITIVE PHASE 3 DATA FOR BEPIROVIRSEN 0001654954-26-005453 001-15170 261028389 34 73910
2026-05-27 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-005405 001-15170 261022935 34 35493
2026-05-26 SD SPECIALIZED DISCLOSURE REPORT 0001999371-26-011448 001-15170 261019922 34 19190
2026-05-26 6-K ADMISSION TO TRADING 0001654954-26-005339 001-15170 261016590 34 29297
2026-05-26 6-K TRANSACTION IN OWN SHARES 0001654954-26-005335 001-15170 261016520 34 47306
2026-05-22 6-K Q2 2026 RESULTS DATE CONFIRMED - 28 JULY 2026 0001654954-26-005250 001-15170 261010726 34 27497
2026-05-20 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-005164 001-15170 261002335 34 35862
2026-05-20 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-005163 001-15170 261002333 34 35862
2026-05-19 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-005102 001-15170 26996610 34 77621
2026-05-18 6-K TRANSACTION IN OWN SHARES 0001654954-26-005052 001-15170 26991321 34 47631
2026-05-18 6-K JAPAN MHLW APPROVES AREXVY FOR ADULTS 18-49 AIR 0001654954-26-005024 001-15170 26990728 34 68432
2026-05-14 13F-HR xslForm13F_X02/primary_doc.xml 0001999371-26-010742 028-26280 26979943 34 9967
2026-05-14 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-004863 001-15170 26977088 34 215133
2026-05-11 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-004654 001-15170 26961494 34 34034
2026-05-11 6-K COLLABORATION WITH CTTQ FOR BEPIROVIRSEN 0001654954-26-004645 001-15170 26960764 34 46920
2026-05-11 6-K GSK - FINAL TRANCHE OF SHARE BUYBACK PROGRAMME 0001654954-26-004643 001-15170 26960748 34 35028
2026-05-06 6-K RESULT OF AGM 0001654954-26-004409 001-15170 26947506 34 109662
2026-05-06 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000315066-26-001214 005-84251 26946766 34 11217
2026-05-05 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-004342 001-15170 26941814 34 39047
2026-05-01 6-K TOTAL VOTING RIGHTS 0001654954-26-004251 001-15170 26930071 34 20095
2026-05-01 6-K HOLDING(S) IN COMPANY 0001654954-26-004250 001-15170 26929989 34 64322
2026-04-29 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-004056 001-15170 26912410 34 57981
2026-04-29 6-K 1ST QUARTER RESULTS 0001654954-26-004051 001-15170 26910654 34 1545662
2026-04-28 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-003992 001-15170 26904629 34 36800
2026-04-28 6-K BEPIROVIRSEN PRIORITY REVIEW US FILING ACCEPTANCE 0001654954-26-003977 001-15170 26903133 34 46153
2026-04-27 6-K EFIMOSFERMIN GRANTED US/EU REGULATORY DESIGNATIONS 0001654954-26-003947 001-15170 26896654 34 44329
2026-04-27 6-K TESARO UPDATE ON ANAPTYSBIO INC. LITIGATION 0001654954-26-003940 001-15170 26896451 34 32242
2026-04-24 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-003895 001-15170 26891416 34 34337
2026-04-23 6-K TRANSACTION IN OWN SHARES 0001654954-26-003814 001-15170 26885376 34 6628519
2026-04-22 6-K TRANSACTION IN OWN SHARES 0001654954-26-003778 001-15170 26881213 34 4076251
2026-04-21 6-K TRANSACTION IN OWN SHARES 0001654954-26-003750 001-15170 26876644 34 3737880
2026-04-20 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-003726 001-15170 26874278 34 35251
2026-04-20 6-K BLENREP APPROVED IN CHINA FOR 2L+ MULTIPLE MYELOMA 0001654954-26-003693 001-15170 26873308 34 63701
2026-04-20 6-K TRANSACTION IN OWN SHARES 0001654954-26-003688 001-15170 26873291 34 3929346
2026-04-17 6-K TRANSACTION IN OWN SHARES 0001654954-26-003629 001-15170 26869338 34 3321280
2026-04-16 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-003598 001-15170 26866490 34 507726
2026-04-16 6-K TRANSACTION IN OWN SHARES 0001654954-26-003565 001-15170 26865634 34 3740554
2026-04-15 6-K GSK COMPLETES ACQUISITION OF 35PHARMA INC. 0001654954-26-003518 001-15170 26862490 34 35889
2026-04-15 6-K TRANSACTION IN OWN SHARES 0001654954-26-003516 001-15170 26862447 34 3536037
2026-04-14 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-003483 001-15170 26859769 34 218294
2026-04-14 6-K TRANSACTION IN OWN SHARES 0001654954-26-003463 001-15170 26859125 34 4078906
2026-04-13 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-003439 001-15170 26856901 34 376156
2026-04-13 6-K GSK PRESENTS POSITIVE DATA FOR BEHOLD 1 B7 H4 ADC 0001654954-26-003422 001-15170 26856385 34 51567
2026-04-13 6-K TRANSACTION IN OWN SHARES 0001654954-26-003420 001-15170 26856366 34 4086896
2026-04-10 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-003401 001-15170 26853830 34 269379
2026-04-10 6-K TRANSACTION IN OWN SHARES 0001654954-26-003393 001-15170 26853120 34 3660575
2026-04-09 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-003371 001-15170 26850636 34 39377
2026-04-09 6-K TRANSACTION IN OWN SHARES 0001654954-26-003362 001-15170 26849758 34 4439501
2026-04-08 6-K EXDENSUR APPROVED FOR CRSWNP IN CHINA 0001654954-26-003334 001-15170 26846551 34 63731
2026-04-08 6-K TRANSACTION IN OWN SHARES 0001654954-26-003331 001-15170 26846546 34 4255537
2026-04-07 6-K TRANSACTION IN OWN SHARES 0001654954-26-003274 001-15170 26842998 34 3870883
2026-04-02 6-K TRANSACTION IN OWN SHARES 0001654954-26-003197 001-15170 26830636 34 4274306
2026-04-01 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-003166 001-15170 26826454 34 57538
2026-04-01 6-K TOTAL VOTING RIGHTS 0001654954-26-003162 001-15170 26826119 34 20674
2026-04-01 6-K TRANSACTION IN OWN SHARES 0001654954-26-003122 001-15170 26824638 34 3704260
2026-04-01 6-K VIIV COMPLETES CHANGES TO MINORITY SHAREHOLDING 0001654954-26-003119 001-15170 26824605 34 37205
2026-03-31 6-K TRANSACTION IN OWN SHARES 0001654954-26-002995 001-15170 26816732 34 3984491
2026-03-30 6-K BEPIROVIRSEN ACCEPTED FOR REVIEW IN CHINA 0001654954-26-002919 001-15170 26809917 34 42261
2026-03-30 6-K EXDENSUR APPROVED FOR SEVERE ASTHMA IN CHINA 0001654954-26-002916 001-15170 26809884 34 61832
2026-03-30 6-K TRANSACTION IN OWN SHARES 0001654954-26-002914 001-15170 26809841 34 4519116
2026-03-27 6-K TRANSACTION IN OWN SHARES 0001654954-26-002851 001-15170 26801091 34 2298716
2026-03-27 6-K BEPIROVIRSEN ACCEPTED FOR REVIEW BY THE EMA 0001654954-26-002848 001-15170 26801084 34 42964
2026-03-26 6-K TRANSACTION IN OWN SHARES 0001654954-26-002780 001-15170 26794306 34 3170145
2026-03-25 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-002744 001-15170 26790765 34 36440
2026-03-25 6-K NOTICE OF AGM 0001654954-26-002728 001-15170 26788700 34 22611
2026-03-25 6-K TRANSACTION IN OWN SHARES 0001654954-26-002709 001-15170 26788328 34 8812707
2026-03-24 6-K TRANSACTION IN OWN SHARES 0001654954-26-002641 001-15170 26784192 34 12118557
2026-03-23 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-002600 001-15170 26780911 34 204094
2026-03-23 6-K ADMISSION TO TRADING 0001654954-26-002596 001-15170 26780634 34 31006
2026-03-23 6-K GSK LUNG CANCER ADC GETS JAPAN ORPHAN DRUG STATUS 0001654954-26-002580 001-15170 26779928 34 42222
2026-03-23 6-K TRANSACTION IN OWN SHARES 0001654954-26-002577 001-15170 26779921 34 8688352
2026-03-20 6-K TRANSACTION IN OWN SHARES 0001654954-26-002514 001-15170 26776085 34 10716140
2026-03-19 6-K LYNAVOY (LINERIXIBAT) APPROVED BY US FDA 0001654954-26-002482 001-15170 26772718 34 47987
2026-03-19 6-K TRANSACTION IN OWN SHARES 0001654954-26-002466 001-15170 26772396 34 10556594
2026-03-18 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-002367 001-15170 26767477 34 37276
2026-03-18 6-K TRANSACTION IN OWN SHARES 0001654954-26-002356 001-15170 26765765 34 7993916
2026-03-17 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-002324 001-15170 26760938 34 36913
2026-03-17 6-K TRANSACTION IN OWN SHARES 0001654954-26-002311 001-15170 26759078 34 7079938
2026-03-16 6-K TRANSACTION IN OWN SHARES 0001654954-26-002266 001-15170 26754571 34 4190327
2026-03-13 6-K US FDA APPROVES AREXVY FOR ADULTS 18-49 AIR 0001654954-26-002214 001-15170 26750141 34 54834
2026-03-13 6-K TRANSACTION IN OWN SHARES 0001654954-26-002208 001-15170 26750059 34 10129686
2026-03-12 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-002183 001-15170 26746789 34 232780
2026-03-12 6-K TRANSACTION IN OWN SHARES 0001654954-26-002166 001-15170 26745755 34 6888084
2026-03-11 6-K TRANSACTION IN OWN SHARES 0001654954-26-002120 001-15170 26741556 34 4625736
2026-03-10 6-K TRANSACTION IN OWN SHARES 0001654954-26-002076 001-15170 26737254 34 4548827
2026-03-09 6-K BOARD COMMITTEE CHANGE 0001654954-26-002019 001-15170 26733841 34 18236
2026-03-09 6-K GSK AND ALFASIGMA AGREE GLOBAL LINERIXIBAT RIGHTS 0001654954-26-002008 001-15170 26733282 34 43024
2026-03-09 6-K TRANSACTION IN OWN SHARES 0001654954-26-002005 001-15170 26733252 34 6387463
2026-03-06 6-K FILING OF GSK PLC 2025 ANNUAL REPORT ON FORM 20-F 0001654954-26-001975 001-15170 26728970 34 22685
2026-03-06 IRANNOTICE IRANNOTICE 0001131399-26-000006 001-15170 26728716 34 373734
2026-03-06 20-F 20-F 0001131399-26-000004 001-15170 26728707 34 101116598 1 1
2026-03-06 6-K TRANSACTION IN OWN SHARES 0001654954-26-001950 001-15170 26728440 34 9795016
2026-03-05 6-K GSK PUBLISHES ANNUAL REPORT 2025 0001654954-26-001917 001-15170 26724518 34 21958
2026-03-05 6-K TRANSACTION IN OWN SHARES 0001654954-26-001907 001-15170 26724445 34 7224083
2026-03-04 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001860 001-15170 26719710 34 34394
2026-03-04 6-K TRANSACTION IN OWN SHARES 0001654954-26-001852 001-15170 26718721 34 9384427
2026-03-03 6-K GSK COMPLETES ACQUISITION OF RAPT THERAPEUTICS 0001654954-26-001801 001-15170 26711856 34 38317
2026-03-03 6-K TRANSACTION IN OWN SHARES 0001654954-26-001790 001-15170 26710979 34 6152119
2026-03-03 SC TO-T/A SC TO-T/A 0001193125-26-086527 22680
2026-03-02 6-K TRANSACTION IN OWN SHARES 0001654954-26-001756 001-15170 26706665 34 5311289
2026-03-02 6-K TOTAL VOTING RIGHTS 0001654954-26-001733 001-15170 26705623 34 20444
2026-02-27 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001650 001-15170 26695957 34 33944
2026-02-27 6-K TRANSACTION IN OWN SHARES 0001654954-26-001625 001-15170 26692582 34 7436356
2026-02-26 6-K LINERIXIBAT ACCEPTED FOR PRIORITY REVIEW IN CHINA 0001654954-26-001580 001-15170 26681615 34 40958
2026-02-26 6-K BEPIROVIRSEN ACCEPTED FOR JAPAN REGULATORY REVIEW 0001654954-26-001578 001-15170 26681605 34 46066
2026-02-26 6-K TRANSACTION IN OWN SHARES 0001654954-26-001575 001-15170 26681579 34 5417869
2026-02-25 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001551 001-15170 26676466 34 33825
2026-02-25 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001547 001-15170 26675658 34 34242
2026-02-25 6-K GSK ENTERS AGREEMENT TO ACQUIRE 35PHARMA 0001654954-26-001533 001-15170 26675231 34 41706
2026-02-25 6-K TRANSACTION IN OWN SHARES 0001654954-26-001531 001-15170 26675196 34 5469685
2026-02-24 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001495 001-15170 26668569 34 53112
2026-02-24 6-K TRANSACTION IN OWN SHARES 0001654954-26-001477 001-15170 26667388 34 5648178
2026-02-24 SC TO-T/A SC TO-T/A 0001193125-26-065083 24318
2026-02-23 6-K TRANSACTION IN OWN SHARES 0001654954-26-001438 001-15170 26661971 34 5492420
2026-02-20 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001425 001-15170 26657423 34 35954
2026-02-20 6-K TRANSACTION IN OWN SHARES 0001654954-26-001411 001-15170 26656631 34 5822887
2026-02-19 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001380 001-15170 26652650 34 36504
2026-02-19 6-K TRANSACTION IN OWN SHARES 0001654954-26-001372 001-15170 26651435 34 5464062
2026-02-18 6-K TRANSACTION IN OWN SHARES 0001654954-26-001330 001-15170 26645365 34 5451186
2026-02-17 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001297 001-15170 26638432 34 55900
2026-02-17 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001295 001-15170 26638379 34 625679
2026-02-17 6-K GSK - FOURTH TRANCHE OF SHARE BUYBACK PROGRAMME 0001654954-26-001288 001-15170 26637617 34 33467
2026-02-17 6-K EXDENSUR APPROVED BY THE EUROPEAN COMMISSION 0001654954-26-001276 001-15170 26636819 34 64313
2026-02-17 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001267 001-15170 26636536 34 343746
2026-02-17 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001265 001-15170 26636444 34 200907
2026-02-17 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001262 001-15170 26636362 34 55929
2026-02-12 13F-HR xslForm13F_X02/primary_doc.xml 0001999371-26-003198 028-26280 26626707 34 10885
2026-02-11 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001125 001-15170 26619644 34 236589
2026-02-11 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001123 001-15170 26619562 34 388576
2026-02-11 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001116 001-15170 26619296 34 76869
2026-02-11 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001113 001-15170 26619257 34 261053
2026-02-10 6-K CHINA CDE ACCEPTS AREXVY ADULTS 60+ APPLICATION 0001654954-26-001068 001-15170 26614460 34 48289
2026-02-09 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-001035 001-15170 26610253 34 36669
2026-02-06 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-000976 001-15170 26605530 34 36778
2026-02-06 6-K NUCALA COPD APPROVED BY THE EUROPEAN COMMISSION 0001654954-26-000970 001-15170 26605371 34 53423
2026-02-05 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-000949 001-15170 26602155 34 57895
2026-02-04 6-K FINAL RESULTS 0001654954-26-000892 001-15170 26596518 34 2409014
2026-02-02 6-K TOTAL VOTING RIGHTS 0001654954-26-000829 001-15170 26586912 34 19235
2026-02-02 SC TO-T SC TO-T 0001193125-26-032610 1323120 1 1
2026-01-26 6-K EUROPEAN COMMISSION APPROVES AREXVY FOR ADULTS 18+ 0001654954-26-000581 001-15170 26558643 34 44119
2026-01-20 SC TO-C SC TO-C 0001193125-26-016553 3961310
2026-01-20 SC TO-C SC TO-C 0001193125-26-016042 70771
2026-01-20 6-K GSK TO ACQUIRE RAPT THERAPEUTICS 0001654954-26-000470 001-15170 26541142 34 55659
2026-01-20 6-K AGREEMENT ON CHANGES TO VIIV MINORITY SHAREHOLDING 0001654954-26-000468 001-15170 26541140 34 42632
2026-01-16 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-000417 001-15170 26538522 34 118987
2026-01-15 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-000375 001-15170 26535168 34 56169
2026-01-13 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-000324 001-15170 26529409 34 1067598
2026-01-07 6-K EC APPROVAL OF SHINGRIX PFS 0001654954-26-000138 001-15170 26513962 34 49065
2026-01-07 6-K POSITIVE PHASE 3 DATA FOR GSK'S BEPIROVIRSEN 0001654954-26-000136 001-15170 26513931 34 44902
2026-01-06 6-K EXDENSUR APPROVED IN JAPAN 0001654954-26-000107 001-15170 26509381 34 77832
2026-01-05 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-26-000071 001-15170 26504872 34 52552
2026-01-05 6-K TOTAL VOTING RIGHTS 0001654954-26-000061 001-15170 26504410 34 20037
2026-01-05 6-K NUCALA FOR ADULTS WITH COPD APPROVED IN CHINA 0001654954-26-000056 001-15170 26503836 34 50659
2025-12-23 6-K GSK TO LOWER DRUG PRICES AND EXPAND ACCESS IN US 0001654954-25-014268 001-15170 251594697 34 33883
2025-12-22 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-014212 001-15170 251591051 34 162411
2025-12-22 6-K TRANSACTION IN OWN SHARES 0001654954-25-014156 001-15170 251589354 34 3651634
2025-12-19 6-K TRANSACTION IN OWN SHARES 0001654954-25-014129 001-15170 251585018 34 3171865
2025-12-18 6-K TRANSACTION IN OWN SHARES 0001654954-25-014074 001-15170 251581206 34 3980612
2025-12-17 6-K EXDENSUR (DEPEMOKIMAB ULLA) APPROVED BY US FDA 0001654954-25-014033 001-15170 251577242 34 59592
2025-12-17 6-K TRANSACTION IN OWN SHARES 0001654954-25-014027 001-15170 251577205 34 3568480
2025-12-16 6-K EXDENSUR (DEPEMOKIMAB) UK MHRA APPROVAL 0001654954-25-013981 001-15170 251573483 34 60510
2025-12-16 6-K TRANSACTION IN OWN SHARES 0001654954-25-013979 001-15170 251573385 34 3601750
2025-12-15 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP 0001999371-25-020336 001-37627 251572044 34 5728
2025-12-15 6-K TRANSACTION IN OWN SHARES 0001654954-25-013922 001-15170 251569973 34 3201099
2025-12-12 6-K DEPEMOKIMAB RECEIVES POSITIVE CHMP OPINION 0001654954-25-013890 001-15170 251566857 34 54300
2025-12-12 6-K NUCALA RECEIVES POSITIVE CHMP OPINION FOR COPD 0001654954-25-013887 001-15170 251566824 34 48412
2025-12-12 6-K POSITIVE CHMP OPINION ON AREXVY FOR ALL ADULTS 18+ 0001654954-25-013882 001-15170 251566696 34 46336
2025-12-12 6-K TRANSACTION IN OWN SHARES 0001654954-25-013879 001-15170 251566653 34 3261711
2025-12-11 6-K BLUJEPA APPROVED IN US FOR GONORRHOEA INDICATION 0001654954-25-013845 001-15170 251564404 34 51677
2025-12-11 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-013834 001-15170 251564104 34 193862
2025-12-11 6-K BLOCK LISTING APPLICATION 0001654954-25-013825 001-15170 251563525 34 18854
2025-12-11 6-K TRANSACTION IN OWN SHARES 0001654954-25-013823 001-15170 251563520 34 3310676
2025-12-10 6-K TRANSACTION IN OWN SHARES 0001654954-25-013792 001-15170 251560804 34 3494743
2025-12-10 6-K GSK'227 US FDA ORPHAN DRUG DESIGNATION IN SCLC 0001654954-25-013788 001-15170 251560767 34 39554
2025-12-09 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-013777 001-15170 251558256 34 35541
2025-12-09 6-K TRANSACTION IN OWN SHARES 0001654954-25-013768 001-15170 251557566 34 3370958
2025-12-08 6-K TRANSACTION IN OWN SHARES 0001654954-25-013741 001-15170 251554643 34 3365746
2025-12-05 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001999371-25-019650 31897
2025-12-05 6-K TRANSACTION IN OWN SHARES 0001654954-25-013692 001-15170 251551184 34 3513396
2025-12-04 6-K TRANSACTION IN OWN SHARES 0001654954-25-013661 001-15170 251548269 34 3024070
2025-12-03 6-K TRANSACTION IN OWN SHARES 0001654954-25-013632 001-15170 251545093 34 2675302
2025-12-02 6-K TRANSACTION IN OWN SHARES 0001654954-25-013604 001-15170 251541607 34 2225715
2025-12-01 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-013579 001-15170 251538547 34 72246
2025-12-01 6-K TOTAL VOTING RIGHTS 0001654954-25-013575 001-15170 251538451 34 19791
2025-12-01 6-K TRANSACTION IN OWN SHARES 0001654954-25-013521 001-15170 251537100 34 2925870
2025-11-28 6-K TRANSACTION IN OWN SHARES 0001654954-25-013497 001-15170 251533610 34 3057655
2025-11-28 6-K TRANSACTION IN OWN SHARES 0001654954-25-013468 001-15170 251532313 34 2168532
2025-11-26 6-K TRANSACTION IN OWN SHARES 0001654954-25-013446 001-15170 251523771 34 2418880
2025-11-25 6-K TRANSACTION IN OWN SHARES 0001654954-25-013418 001-15170 251514986 34 2223867
2025-11-24 6-K TRANSACTION IN OWN SHARES 0001654954-25-013399 001-15170 251509536 34 2325652
2025-11-21 6-K INITIATION OF LITIGATION AGAINST ANAPTYSBIO INC 0001654954-25-013351 001-15170 251504692 34 29120
2025-11-21 6-K TRANSACTION IN OWN SHARES 0001654954-25-013348 001-15170 251504600 34 4461435
2025-11-20 6-K TRANSACTION IN OWN SHARES 0001654954-25-013320 001-15170 251501190 34 3029427
2025-11-19 6-K TRANSFER OF TREASURY SHARES 0001654954-25-013250 001-15170 251496708 34 22295
2025-11-19 6-K TRANSACTION IN OWN SHARES 0001654954-25-013248 001-15170 251496689 34 2906108
2025-11-18 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-013187 001-15170 251493295 34 78109
2025-11-18 6-K TRANSACTION IN OWN SHARES 0001654954-25-013178 001-15170 251492900 34 2127607
2025-11-17 6-K TRANSACTION IN OWN SHARES 0001654954-25-013117 001-15170 251489232 34 2101535
2025-11-14 6-K TRANSACTION IN OWN SHARES 0001654954-25-013014 001-15170 251481036 34 1942282
2025-11-13 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-012969 001-15170 251476602 34 194973
2025-11-13 6-K TRANSACTION IN OWN SHARES 0001654954-25-012955 001-15170 251475280 34 1841199
2025-11-12 6-K BLOCK LISTING INTERIM REVIEW 0001654954-25-012888 001-15170 251471371 34 45460
2025-11-12 6-K TRANSACTION IN OWN SHARES 0001654954-25-012845 001-15170 251470301 34 1619795
2025-11-12 6-K TRANSACTION IN OWN SHARES 0001654954-25-012792 001-15170 251468220 34 2047200
2025-11-10 6-K GSK PUBLISHES PROVISIONAL DIVIDEND DATES 0001654954-25-012745 001-15170 251465027 34 28770
2025-11-10 6-K TRANSACTION IN OWN SHARES 0001654954-25-012720 001-15170 251464303 34 1871577
2025-11-07 6-K TRANSACTION IN OWN SHARES 0001654954-25-012679 001-15170 251460285 34 2412336
2025-11-06 6-K TRANSACTION IN OWN SHARES 0001654954-25-012632 001-15170 251456228 34 1880016
2025-11-05 6-K TRANSACTION IN OWN SHARES 0001654954-25-012587 001-15170 251451615 34 1276405
2025-11-04 6-K TRANSACTION IN OWN SHARES 0001654954-25-012543 001-15170 251446426 34 2265434
2025-11-03 6-K TOTAL VOTING RIGHTS 0001654954-25-012505 001-15170 251443266 34 16649
2025-11-03 6-K TRANSACTION IN OWN SHARES 0001654954-25-012444 001-15170 251442020 34 2071432
2025-10-31 6-K TRANSACTION IN OWN SHARES 0001654954-25-012388 001-15170 251437936 34 1449907
2025-10-30 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-012360 001-15170 251433467 34 49181
2025-10-30 6-K TRANSACTION IN OWN SHARES 0001654954-25-012344 001-15170 251432333 34 1264517
2025-10-29 6-K TRANSACTION IN OWN SHARES 0001654954-25-012308 001-15170 251428276 34 2157054
2025-10-29 6-K 3RD QUARTER RESULTS 0001654954-25-012307 001-15170 251428198 34 2269344
2025-10-28 6-K TRANSACTION IN OWN SHARES 0001654954-25-012261 001-15170 251421458 34 1386144
2025-10-28 6-K GSK ADC GETS ORPHAN DRUG DESIGNATION IN THE EU 0001654954-25-012259 001-15170 251421331 34 37900
2025-10-27 6-K TRANSACTION IN OWN SHARES 0001654954-25-012225 001-15170 251417637 34 4438700
2025-10-24 6-K BLENREP APPROVED BY US FDA IN MULTIPLE MYELOMA 0001654954-25-012176 001-15170 251414461 34 69450
2025-10-24 6-K TRANSACTION IN OWN SHARES 0001654954-25-012159 001-15170 251414223 34 2803658
2025-10-23 6-K TRANSACTION IN OWN SHARES 0001654954-25-012082 001-15170 251411408 34 2042180
2025-10-22 6-K POSITIVE DATA FOR LOW CARBON VERSION VENTOLIN MDI 0001654954-25-012045 001-15170 251408712 34 39984
2025-10-22 6-K TRANSACTION IN OWN SHARES 0001654954-25-012042 001-15170 251408653 34 1809296
2025-10-22 6-K LATOZINEMAB DATA READ OUT 0001654954-25-012035 001-15170 251408582 34 32032
2025-10-21 6-K POSITIVE CHMP OPINION FOR GSK ON SHINGRIX PFS 0001654954-25-011999 001-15170 251405380 34 49706
2025-10-21 6-K TRANSACTION IN OWN SHARES 0001654954-25-011992 001-15170 251405325 34 1699181
2025-10-21 6-K GSK SHARE POSITIVE PH3 DATA ON TEBIPENEM HBR 0001654954-25-011990 001-15170 251405313 34 58296
2025-10-20 6-K TRANSACTION IN OWN SHARES 0001654954-25-011945 001-15170 251402286 34 4977889
2025-10-17 6-K TRANSACTION IN OWN SHARES 0001654954-25-011905 001-15170 251398996 34 3754629
2025-10-16 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-011875 001-15170 251397008 34 69872
2025-10-16 6-K TRANSACTION IN OWN SHARES 0001654954-25-011846 001-15170 251396393 34 4675724
2025-10-15 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-011805 001-15170 251394093 34 322690
2025-10-15 6-K TRANSACTION IN OWN SHARES 0001654954-25-011786 001-15170 251393351 34 3400184
2025-10-14 6-K GSK RECEIVES EXPANDED SHINGRIX APPROVAL IN CHINA 0001654954-25-011717 001-15170 251389872 34 51136
2025-10-14 6-K TRANSACTION IN OWN SHARES 0001654954-25-011710 001-15170 251389647 34 2350087
2025-10-14 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-011702 001-15170 251389578 34 614176
2025-10-14 6-K TRANSACTION IN OWN SHARES 0001654954-25-011685 001-15170 251389176 34 2541574
2025-10-10 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-011651 001-15170 251386850 34 212023
2025-10-10 6-K TRANSACTION IN OWN SHARES 0001654954-25-011629 001-15170 251386220 34 1808364
2025-10-09 6-K TRANSACTION IN OWN SHARES 0001654954-25-011584 001-15170 251383620 34 2975970
2025-10-08 6-K TRANSACTION IN OWN SHARES 0001654954-25-011559 001-15170 251381195 34 3608518
2025-10-07 6-K TRANSACTION IN OWN SHARES 0001654954-25-011522 001-15170 251378202 34 4606939
2025-10-06 6-K TRANSACTION IN OWN SHARES 0001654954-25-011459 001-15170 251375593 34 4289762
2025-10-03 6-K TRANSACTION IN OWN SHARES 0001654954-25-011415 001-15170 251372036 34 4263431
2025-10-02 6-K TRANSACTION IN OWN SHARES 0001654954-25-011359 001-15170 251367003 34 4155217
2025-10-01 6-K TOTAL VOTING RIGHTS 0001654954-25-011307 001-15170 251362872 34 16884
2025-10-01 6-K TRANSACTION IN OWN SHARES 0001654954-25-011296 001-15170 251362596 34 2188674
2025-09-30 6-K GSK - THIRD TRANCHE OF SHARE BUYBACK PROGRAMME 0001654954-25-011211 001-15170 251358185 34 31827
2025-09-29 6-K GSK APPOINTS CEO DESIGNATE 0001654954-25-011173 001-15170 251352052 34 51310
2025-09-22 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-010981 001-15170 251329260 34 164927
2025-09-19 6-K TRANSACTION IN OWN SHARES 0001654954-25-010923 001-15170 251324864 34 407066
2025-09-18 6-K TRANSACTION IN OWN SHARES 0001654954-25-010888 001-15170 251321767 34 3934641
2025-09-17 6-K GSK US INVESTMENT ANNOUNCEMENT 0001654954-25-010843 001-15170 251318766 34 34342
2025-09-17 6-K TRANSACTION IN OWN SHARES 0001654954-25-010835 001-15170 251318754 34 2505715
2025-09-16 6-K TRANSACTION IN OWN SHARES 0001654954-25-010794 001-15170 251316017 34 9441445
2025-09-15 6-K TRANSACTION IN OWN SHARES 0001654954-25-010739 001-15170 251313327 34 4789129
2025-09-12 6-K TRANSACTION IN OWN SHARES 0001654954-25-010672 001-15170 251309994 34 4671918
2025-09-11 6-K TRANSACTION IN OWN SHARES 0001654954-25-010634 001-15170 251307223 34 2308296
2025-09-10 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-010599 001-15170 251305140 34 199662
2025-09-10 6-K TRANSACTION IN OWN SHARES 0001654954-25-010565 001-15170 251304580 34 1455219
2025-09-09 6-K TRANSACTION IN OWN SHARES 0001654954-25-010505 001-15170 251301670 34 8031449
2025-09-08 6-K TRANSACTION IN OWN SHARES 0001654954-25-010455 001-15170 251298549 34 6283960
2025-09-05 6-K TRANSACTION IN OWN SHARES 0001654954-25-010429 001-15170 251294997 34 2620616
2025-09-04 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-010402 001-15170 251292353 34 32971
2025-09-04 6-K TRANSACTION IN OWN SHARES 0001654954-25-010384 001-15170 251291867 34 5562413
2025-09-03 6-K TRANSACTION IN OWN SHARES 0001654954-25-010336 001-15170 251287712 34 2512357
2025-09-02 6-K TRANSACTION IN OWN SHARES 0001654954-25-010285 001-15170 251283363 34 5770654
2025-09-02 6-K TOTAL VOTING RIGHTS 0001654954-25-010263 001-15170 251283104 34 16408
2025-09-02 6-K TRANSACTION IN OWN SHARES 0001654954-25-010241 001-15170 251282901 34 7105126
2025-08-29 6-K TRANSACTION IN OWN SHARES 0001654954-25-010165 001-15170 251275860 34 4909272
2025-08-28 6-K TRANSACTION IN OWN SHARES 0001654954-25-010110 001-15170 251267383 34 3547721
2025-08-27 6-K TRANSACTION IN OWN SHARES 0001654954-25-010072 001-15170 251259812 34 2612860
2025-08-26 6-K TRANSACTION IN OWN SHARES 0001654954-25-009996 001-15170 251252628 34 5366169
2025-08-22 6-K TRANSACTION IN OWN SHARES 0001654954-25-009943 001-15170 251242534 34 8295349
2025-08-21 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-009886 001-15170 251239151 34 34230
2025-08-21 6-K TRANSACTION IN OWN SHARES 0001654954-25-009874 001-15170 251238318 34 5001768
2025-08-20 6-K TRANSACTION IN OWN SHARES 0001654954-25-009835 001-15170 251233763 34 6067125
2025-08-19 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-009804 001-15170 251230147 34 75628
2025-08-19 6-K TRANSACTION IN OWN SHARES 0001654954-25-009782 001-15170 251229586 34 4382563
2025-08-18 6-K TRANSACTION IN OWN SHARES 0001654954-25-009735 001-15170 251226221 34 2227064
2025-08-15 6-K TRANSACTION IN OWN SHARES 0001654954-25-009682 001-15170 251222375 34 5675675
2025-08-14 6-K TRANSACTION IN OWN SHARES 0001654954-25-009525 001-15170 251213965 34 1066515
2025-08-13 SCHEDULE 13D xslSCHEDULE_13D_X01/primary_doc.xml 0001999371-25-011273 34262
2025-08-13 6-K TRANSACTION IN OWN SHARES 0001654954-25-009467 001-15170 251208791 34 4354867
2025-08-12 6-K DIRECTOR/PDMR SHAREHOLDING 0001654954-25-009404 001-15170 251205567 34 197783
2025-08-12 6-K TRANSACTION IN OWN SHARES 0001654954-25-009371 001-15170 251203901 34 5683172
2025-08-11 6-K FDA TO REVIEW GONORRHEA INDICATION FOR GEPOTIDACIN 0001654954-25-009314 001-15170 251200113 34 49154
2025-08-11 6-K TRANSACTION IN OWN SHARES 0001654954-25-009310 001-15170 251200064 34 5898686
2025-08-08 6-K CUREVAC/BIONTECH MRNA PATENT LITIGATION SETTLEMENT 0001654954-25-009240 001-15170 251196133 34 32942
2025-08-08 6-K TRANSACTION IN OWN SHARES 0001654954-25-009238 001-15170 251196130 34 7488943
2025-08-07 6-K TRANSACTION IN OWN SHARES 0001654954-25-009167 001-15170 251191676 34 8475669
2025-08-06 6-K TRANSACTION IN OWN SHARES 0001654954-25-009091 001-15170 251187342 34 7409984
2025-08-05 6-K TRANSACTION IN OWN SHARES 0001654954-25-008956 001-15170 251182789 34 5221364
2025-08-04 6-K TRANSACTION IN OWN SHARES 0001654954-25-008890 001-15170 251177928 34 10345128
2025-08-01 6-K TOTAL VOTING RIGHTS 0001654954-25-008811 001-15170 251175184 34 16590
2025-08-01 6-K TRANSACTION IN OWN SHARES 0001654954-25-008795 001-15170 251174512 34 37686
2025-07-31 6-K TRANSACTION IN OWN SHARES 0001654954-25-008684 001-15170 251169548 34 5122158

Latest XBRL company facts

One latest value per concept from companyfacts (432 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 4.32B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ffd NetFeeAmt NetFeeAmt USD 261,614.44 2026-10-13 S-8 2026-10-13 0001193125-26-420025
ffd TtlFeeAmt TtlFeeAmt USD 261,614.44 2026-10-13 S-8 2026-10-13 0001193125-26-420025
ffd TtlOfferingAmt TtlOfferingAmt USD 3.01B 2026-10-13 S-8 2026-10-13 0001193125-26-420025
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-10-13 S-8 2026-10-13 0001193125-26-420025
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-06-22 SC TO-T 2026-06-24 0001193125-26-280246
ffd TtlTxValtn TtlTxValtn USD 10.63B 2026-06-22 SC TO-T 2026-06-24 0001193125-26-280246
ifrs-full Accruals Accruals GBP 6.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AccrualsAndDeferredIncome AccrualsAndDeferredIncome GBP 104.00M 2017-12-31 2017 FY 20-F/A 2018-03-20 0001193125-18-088407
ifrs-full AccruedIncome AccruedIncome GBP 13.00M 2020-12-31 2020 FY 20-F 2021-03-12 0001193125-21-079417
ifrs-full AccruedIncomeOtherThanContractAssets AccruedIncomeOtherThanContractAssets GBP 13.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AcquisitiondateFairValueOfTotalConsiderationTransferred AcquisitiondateFairValueOfTotalConsiderationTransferred GBP 2.01B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AcquisitionsThroughBusinessCombinationsOtherProvisions AcquisitionsThroughBusinessCombinationsOtherProvisions GBP 23.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AcquisitionsThroughBusinessCombinationsRightofuseAssets AcquisitionsThroughBusinessCombinationsRightofuseAssets GBP 1.00M 2023-01-01 2023-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full ActuarialAssumptionOfDiscountRates ActuarialAssumptionOfDiscountRates pure 0.07 2017-12-31 2017 FY 20-F/A 2018-03-20 0001193125-18-088407
ifrs-full ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset GBP -62.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset GBP 211.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset GBP -99.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AdditionalProvisionsOtherProvisions AdditionalProvisionsOtherProvisions GBP 840.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AdditionalRecognitionGoodwill AdditionalRecognitionGoodwill GBP 1.13B 2022-01-01 2022-12-31 2023 FY 20-F 2024-03-05 0001131399-24-000007
ifrs-full AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets GBP 181.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AdditionsToRightofuseAssets AdditionsToRightofuseAssets GBP 215.00M 2021-01-01 2021-12-31 2021 FY 20-F 2022-03-08 0001193125-22-068957
ifrs-full AdjustedWeightedAverageShares AdjustedWeightedAverageShares shares 4.12B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AdjustmentsForAmortisationExpense AdjustmentsForAmortisationExpense GBP 1.26B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AdjustmentsForCurrentTaxOfPriorPeriod AdjustmentsForCurrentTaxOfPriorPeriod GBP -49.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AdjustmentsForDecreaseIncreaseInInventories AdjustmentsForDecreaseIncreaseInInventories GBP -140.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables GBP -484.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AdjustmentsForDecreaseIncreaseInTradeAccountReceivable AdjustmentsForDecreaseIncreaseInTradeAccountReceivable GBP -613.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AdjustmentsForDepreciationExpense AdjustmentsForDepreciationExpense GBP 1.06B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AdjustmentsForFairValueGainsLosses AdjustmentsForFairValueGainsLosses GBP 45.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AdjustmentsForFinanceIncomeCost AdjustmentsForFinanceIncomeCost GBP -532.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates GBP 0 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AdjustmentsForIncomeTaxExpense AdjustmentsForIncomeTaxExpense GBP 1.11B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities GBP -1.14B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AdjustmentsForIncreaseDecreaseInOtherOperatingPayables AdjustmentsForIncreaseDecreaseInOtherOperatingPayables GBP 343.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AdjustmentsForIncreaseDecreaseInTradeAccountPayable AdjustmentsForIncreaseDecreaseInTradeAccountPayable GBP 131.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AdjustmentsForReconcileProfitLoss AdjustmentsForReconcileProfitLoss GBP 2.65B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AdjustmentsForSharebasedPayments AdjustmentsForSharebasedPayments GBP 374.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AdvertisingExpense AdvertisingExpense GBP 738.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AmortisationIntangibleAssetsOtherThanGoodwill AmortisationIntangibleAssetsOtherThanGoodwill GBP 1.26B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ApplicableTaxRate ApplicableTaxRate pure 0.19 2022-01-01 2022-12-31 2022 FY 20-F 2023-03-10 0001193125-23-067105
ifrs-full Assets Assets GBP 61.12B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AuditorsRemuneration AuditorsRemuneration GBP 23.30M 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full AuditorsRemunerationForAuditServices AuditorsRemunerationForAuditServices GBP 20.90M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AuditorsRemunerationForOtherServices AuditorsRemunerationForOtherServices GBP 0 2021-01-01 2021-12-31 2021 FY 20-F 2022-03-08 0001193125-22-068957
ifrs-full AuditorsRemunerationForTaxServices AuditorsRemunerationForTaxServices GBP 100,000 2018-01-01 2018-12-31 2020 FY 20-F 2021-03-12 0001193125-21-079417
ifrs-full AverageEffectiveTaxRate AverageEffectiveTaxRate pure 0.15 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full AverageNumberOfEmployees AverageNumberOfEmployees numberOfEmployees 68,307 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full BankOverdraftsClassifiedAsCashEquivalents BankOverdraftsClassifiedAsCashEquivalents GBP 190.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full BasicEarningsLossPerShare BasicEarningsLossPerShare GBP/shares 1.411 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full BasicEarningsLossPerShareFromContinuingOperations BasicEarningsLossPerShareFromContinuingOperations GBP/shares 0.632 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full BasicEarningsLossPerShareFromDiscontinuedOperations BasicEarningsLossPerShareFromDiscontinuedOperations GBP/shares 0 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full Borrowings Borrowings GBP 14.45B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full BrandNames BrandNames GBP 18.42B 2021-12-31 2021 FY 20-F 2022-03-08 0001193125-22-068957
ifrs-full CapitalisationRateOfBorrowingCostsEligibleForCapitalisation CapitalisationRateOfBorrowingCostsEligibleForCapitalisation pure 0.04 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full Cash Cash GBP 761.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CashAndCashEquivalents CashAndCashEquivalents GBP 3.40B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CashAndCashEquivalentsClassifiedAsPartOfDisposalGroupHeldForSale CashAndCashEquivalentsClassifiedAsPartOfDisposalGroupHeldForSale GBP 0 2021-12-31 2021 FY 20-F 2022-03-08 0001193125-22-068957
ifrs-full CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup GBP 247.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition GBP 3.21B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CashAndCashEquivalentsRecognisedAsOfAcquisitionDate CashAndCashEquivalentsRecognisedAsOfAcquisitionDate GBP 78.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CashEquivalents CashEquivalents GBP 2.64B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities GBP -27.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CashFlowsFromUsedInFinancingActivities CashFlowsFromUsedInFinancingActivities GBP -3.69B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CashFlowsFromUsedInFinancingActivitiesContinuingOperations CashFlowsFromUsedInFinancingActivitiesContinuingOperations GBP -4.73B 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations GBP 0 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings GBP 1.08B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CashFlowsFromUsedInInvestingActivities CashFlowsFromUsedInInvestingActivities GBP -4.23B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CashFlowsFromUsedInInvestingActivitiesContinuingOperations CashFlowsFromUsedInInvestingActivitiesContinuingOperations GBP -1.23B 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations GBP 0 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full CashFlowsFromUsedInOperatingActivities CashFlowsFromUsedInOperatingActivities GBP 7.74B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CashFlowsFromUsedInOperatingActivitiesContinuingOperations CashFlowsFromUsedInOperatingActivitiesContinuingOperations GBP 6.55B 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations GBP 0 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full CashFlowsFromUsedInOperations CashFlowsFromUsedInOperations GBP 8.94B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities GBP 1.69B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CashOutflowForLeases CashOutflowForLeases GBP 260.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CashTransferred CashTransferred GBP 12.00M 2019-12-31 2021 FY 20-F 2022-03-08 0001193125-22-068957
ifrs-full CommercialPapersIssued CommercialPapersIssued GBP 1.08B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ComprehensiveIncome ComprehensiveIncome GBP 6.78B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ComprehensiveIncomeAttributableToNoncontrollingInterests ComprehensiveIncomeAttributableToNoncontrollingInterests GBP 555.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ComprehensiveIncomeAttributableToOwnersOfParent ComprehensiveIncomeAttributableToOwnersOfParent GBP 6.23B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ComprehensiveIncomeFromContinuingOperations ComprehensiveIncomeFromContinuingOperations GBP -1.19B 2022-01-01 2022-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full ComprehensiveIncomeFromDiscontinuedOperations ComprehensiveIncomeFromDiscontinuedOperations GBP 356.00M 2022-01-01 2022-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full ContingentConsiderationRecognisedAsOfAcquisitionDate ContingentConsiderationRecognisedAsOfAcquisitionDate GBP 482.00M 2022-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full ContingentLiabilitiesRecognisedInBusinessCombination ContingentLiabilitiesRecognisedInBusinessCombination GBP 6.73B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ContingentRentsRecognisedAsExpenseClassifiedAsOperatingLease ContingentRentsRecognisedAsExpenseClassifiedAsOperatingLease GBP 12.00M 2018-01-01 2018-12-31 2018 FY 20-F 2019-03-15 0001193125-19-076716
ifrs-full ContractLiabilities ContractLiabilities GBP 153.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ContractualCommitmentsForAcquisitionOfIntangibleAssets ContractualCommitmentsForAcquisitionOfIntangibleAssets GBP 17.05B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment GBP 764.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset GBP 283.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CostOfInventoriesRecognisedAsExpenseDuringPeriod CostOfInventoriesRecognisedAsExpenseDuringPeriod GBP 6.36B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CostOfSales CostOfSales GBP 9.02B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity GBP 24.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CurrentAssets CurrentAssets GBP 17.51B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners GBP 113.00M 2017-12-31 2017 FY 20-F/A 2018-03-20 0001193125-18-088407
ifrs-full CurrentDerivativeFinancialAssets CurrentDerivativeFinancialAssets GBP 121.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CurrentDerivativeFinancialLiabilities CurrentDerivativeFinancialLiabilities GBP 75.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading GBP 0 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full CurrentLeaseLiabilities CurrentLeaseLiabilities GBP 137.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CurrentLiabilities CurrentLiabilities GBP 21.39B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax GBP 138.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CurrentRawMaterialsAndCurrentProductionSupplies CurrentRawMaterialsAndCurrentProductionSupplies GBP 608.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CurrentServiceCostNetDefinedBenefitLiabilityAsset CurrentServiceCostNetDefinedBenefitLiabilityAsset GBP 92.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CurrentTaxAssets CurrentTaxAssets GBP 288.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods GBP 1.40B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes GBP 169.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CurrentTaxLiabilities CurrentTaxLiabilities GBP 498.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full CurrentTaxLiabilitiesNoncurrent CurrentTaxLiabilitiesNoncurrent GBP 0 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity GBP 7.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DebtSecurities DebtSecurities GBP 16.89B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions GBP -31.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DecreaseThroughClassifiedAsHeldForSaleRightofuseAssets DecreaseThroughClassifiedAsHeldForSaleRightofuseAssets GBP 16.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DecreaseThroughTransferToLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSaleOtherProvisions DecreaseThroughTransferToLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSaleOtherProvisions GBP 1.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DeferredIncome DeferredIncome GBP 361.00M 2020-12-31 2020 FY 20-F 2021-03-12 0001193125-21-079417
ifrs-full DeferredIncomeClassifiedAsNoncurrent DeferredIncomeClassifiedAsNoncurrent GBP 21.00M 2020-12-31 2020 FY 20-F 2021-03-12 0001193125-21-079417
ifrs-full DeferredTaxAssets DeferredTaxAssets GBP 6.52B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DeferredTaxExpenseIncome DeferredTaxExpenseIncome GBP -283.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DeferredTaxExpenseIncomeRecognisedInProfitOrLoss DeferredTaxExpenseIncomeRecognisedInProfitOrLoss GBP 396.00M 2018-01-01 2018-12-31 2018 FY 20-F 2019-03-15 0001193125-19-076716
ifrs-full DeferredTaxLiabilities DeferredTaxLiabilities GBP 291.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate GBP 316.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DeferredTaxLiabilityAsset DeferredTaxLiabilityAsset GBP -6.23B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity GBP 17.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DefinedBenefitObligationAtPresentValue DefinedBenefitObligationAtPresentValue GBP 12.85B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DepreciationAndAmortisationExpense DepreciationAndAmortisationExpense GBP 2.31B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DepreciationPropertyPlantAndEquipment DepreciationPropertyPlantAndEquipment GBP 850.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DepreciationRightofuseAssets DepreciationRightofuseAssets GBP 206.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DerivativeFinancialAssets DerivativeFinancialAssets GBP 156.00M 2016-12-31 2017 FY 20-F/A 2018-03-20 0001193125-18-088407
ifrs-full DerivativeFinancialAssetsHeldForTrading DerivativeFinancialAssetsHeldForTrading GBP 15.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DerivativeFinancialLiabilities DerivativeFinancialLiabilities GBP 21.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DerivativeFinancialLiabilitiesHeldForTrading DerivativeFinancialLiabilitiesHeldForTrading GBP 54.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DescriptionOfDiscountRatesAppliedToCashFlowProjections DescriptionOfDiscountRatesAppliedToCashFlowProjections pure 0.075 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DilutedEarningsLossPerShare DilutedEarningsLossPerShare GBP/shares 1.388 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DilutedEarningsLossPerShareFromContinuingOperations DilutedEarningsLossPerShareFromContinuingOperations GBP/shares 0.622 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full DilutedEarningsLossPerShareFromDiscontinuedOperations DilutedEarningsLossPerShareFromDiscontinuedOperations GBP/shares 0 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares shares 66.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DisposalsPropertyPlantAndEquipment DisposalsPropertyPlantAndEquipment GBP 44.00M 2019-01-01 2019-12-31 2021 FY 20-F 2022-03-08 0001193125-22-068957
ifrs-full DisposalsRightofuseAssets DisposalsRightofuseAssets GBP 45.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DistributionCosts DistributionCosts GBP 202.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DividendsPaid DividendsPaid GBP 2.56B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DividendsPaidClassifiedAsFinancingActivities DividendsPaidClassifiedAsFinancingActivities GBP -3.91B 2017-01-01 2017-12-31 2018 FY 20-F 2019-03-15 0001193125-19-076716
ifrs-full DividendsPaidOrdinaryShares DividendsPaidOrdinaryShares GBP 2.66B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DividendsPaidOrdinarySharesPerShare DividendsPaidOrdinarySharesPerShare GBP/shares 0.66 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities GBP 2.56B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities GBP 412.00M 2023-01-01 2023-12-31 2023 FY 20-F 2024-03-05 0001131399-24-000007
ifrs-full DividendsReceivedClassifiedAsInvestingActivities DividendsReceivedClassifiedAsInvestingActivities GBP 220.00M 2023-01-01 2023-12-31 2023 FY 20-F 2024-03-05 0001131399-24-000007
ifrs-full DividendsReceivedFromInvestmentsAccountedForUsingEquityMethodClassifiedAsInvestingActivities DividendsReceivedFromInvestmentsAccountedForUsingEquityMethodClassifiedAsInvestingActivities GBP 67.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full DividendsRecognisedAsDistributionsToNoncontrollingInterests DividendsRecognisedAsDistributionsToNoncontrollingInterests GBP 391.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full EffectOfExchangeRateChangesOnCashAndCashEquivalents EffectOfExchangeRateChangesOnCashAndCashEquivalents GBP -19.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full EmployeeBenefitsExpense EmployeeBenefitsExpense GBP 8.77B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full Equity Equity GBP 15.96B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full EquityAndLiabilities EquityAndLiabilities GBP 16.70B 2017-12-31 2017 FY 20-F/A 2018-03-20 0001193125-18-088407
ifrs-full EquityAttributableToOwnersOfParent EquityAttributableToOwnersOfParent GBP 16.38B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full EstimatedFinancialEffectOfContingentLiabilities EstimatedFinancialEffectOfContingentLiabilities GBP 38.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ExpenseDueToUnwindingOfDiscountOnProvisions ExpenseDueToUnwindingOfDiscountOnProvisions GBP 29.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ExpenseFromSharebasedPaymentTransactionsWithEmployees ExpenseFromSharebasedPaymentTransactionsWithEmployees GBP 390.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ExpenseOfRestructuringActivities ExpenseOfRestructuringActivities GBP 109.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed GBP 2.00M 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed GBP 13.00M 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities GBP 15.00M 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full FinanceCosts FinanceCosts GBP 701.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full FinanceIncome FinanceIncome GBP 169.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full FinanceLeaseLiabilities FinanceLeaseLiabilities GBP 68 2018-12-31 2018 FY 20-F 2019-03-15 0001193125-19-076716
ifrs-full FinancialAssets FinancialAssets GBP 11.07B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full FinancialAssetsAtFairValue FinancialAssetsAtFairValue GBP 11.07B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities GBP 500,000 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount FinancialAssetsWithModifiedContractualCashFlowsWhileLossAllowanceMeasuredAtLifetimeExpectedCreditLossesForWhichLossAllowanceChangedDuringReportingPeriodTo12monthExpectedCreditLossesGrossCarryingAmount GBP 15.00M 2018-12-31 2018 FY 20-F 2019-03-15 0001193125-19-076716
ifrs-full FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue GBP 0 2019-12-31 2019 FY 20-F 2020-03-06 0001193125-20-065064
ifrs-full FinancialLiabilities FinancialLiabilities GBP 37.27B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full FinancialLiabilitiesAtFairValue FinancialLiabilitiesAtFairValue GBP 37.26B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full FinishedGoods FinishedGoods GBP 1.62B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full FutureFinanceChargeOnFinanceLease FutureFinanceChargeOnFinanceLease GBP 16 2018-12-31 2018 FY 20-F 2019-03-15 0001193125-19-076716
ifrs-full GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss GBP 0 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full GainLossOnRemeasurementOfReimbursementRights GainLossOnRemeasurementOfReimbursementRights GBP 1.19B 2017-01-01 2017-12-31 2017 FY 20-F/A 2018-03-20 0001193125-18-088407
ifrs-full GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset GainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset GBP 0 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full GainsLossesOnCashFlowHedgesBeforeTax GainsLossesOnCashFlowHedgesBeforeTax GBP -41.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full GainsLossesOnCashFlowHedgesNetOfTax GainsLossesOnCashFlowHedgesNetOfTax GBP 513.00M 2018-01-01 2018-12-31 2020 FY 20-F 2021-03-12 0001193125-21-079417
ifrs-full GainsLossesOnChangeInFairValueOfDerivatives GainsLossesOnChangeInFairValueOfDerivatives GBP 0 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax GBP 15.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full GainsLossesOnChangeInValueOfTimeValueOfOptionsNetOfTax GainsLossesOnChangeInValueOfTimeValueOfOptionsNetOfTax GBP 4.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full GainsLossesOnDisposalsOfInvestments GainsLossesOnDisposalsOfInvestments GBP 0 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full GainsLossesOnDisposalsOfNoncurrentAssets GainsLossesOnDisposalsOfNoncurrentAssets GBP 6.00M 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full GainsLossesOnExchangeDifferencesOnTranslationBeforeTax GainsLossesOnExchangeDifferencesOnTranslationBeforeTax GBP -22.00M 2023-01-01 2023-12-31 2023 FY 20-F 2024-03-05 0001131399-24-000007
ifrs-full GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss GBP 9.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLossMandatorilyMeasuredAtFairValue GBP 337.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeBeforeTax GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeBeforeTax GBP -14.00M 2017-01-01 2017-12-31 2019 FY 20-F 2020-03-06 0001193125-20-065064
ifrs-full GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss GBP 892.00M 2020-01-01 2020-12-31 2020 FY 20-F 2021-03-12 0001193125-21-079417
ifrs-full GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations GainsLossesOnIneffectivenessOfHedgesOfNetInvestmentsInForeignOperations GBP 12.00M 2022-01-01 2022-12-31 2022 FY 20-F 2023-03-10 0001193125-23-067105
ifrs-full GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsBeforeTax GainsLossesOnRemeasuringAvailableforsaleFinancialAssetsBeforeTax GBP -14.00M 2017-01-01 2017-12-31 2019 FY 20-F 2020-03-06 0001193125-20-065064
ifrs-full GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementAssets GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementAssets GBP 160.00M 2020-01-01 2020-12-31 2020 FY 20-F 2021-03-12 0001193125-21-079417
ifrs-full GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets GainsLossesRecognisedInProfitOrLossFairValueMeasurementAssets GBP 1.27B 2020-01-01 2020-12-31 2020 FY 20-F 2021-03-12 0001193125-21-079417
ifrs-full GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments GainsLossesRecognisedInProfitOrLossFairValueMeasurementEntitysOwnEquityInstruments GBP -24.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full GainsOnDisposalsOfInvestments GainsOnDisposalsOfInvestments GBP 37.00M 2017-01-01 2017-12-31 2019 FY 20-F 2020-03-06 0001193125-20-065064
ifrs-full Goodwill Goodwill GBP 7.02B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full GoodwillRecognisedAsOfAcquisitionDate GoodwillRecognisedAsOfAcquisitionDate GBP 315.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full GrossFinanceLeaseObligations GrossFinanceLeaseObligations GBP 84 2018-12-31 2018 FY 20-F 2019-03-15 0001193125-19-076716
ifrs-full GrossProfit GrossProfit GBP 23.65B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full HedgingInstrumentAssets HedgingInstrumentAssets GBP 130.00M 2023-12-31 2023 FY 20-F 2024-03-05 0001131399-24-000007
ifrs-full HedgingInstrumentLiabilities HedgingInstrumentLiabilities GBP 189.00M 2019-12-31 2019 FY 20-F 2020-03-06 0001193125-20-065064
ifrs-full IdentifiableAssetsAcquiredLiabilitiesAssumed IdentifiableAssetsAcquiredLiabilitiesAssumed GBP 1.70B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate GBP 1.97B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ImpairmentLoss ImpairmentLoss GBP 33.00M 2023-01-01 2023-12-31 2023 FY 20-F 2024-03-05 0001131399-24-000007
ifrs-full ImpairmentLossRecognisedInProfitOrLoss ImpairmentLossRecognisedInProfitOrLoss GBP 1.11B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ImpairmentLossRecognisedInProfitOrLossGoodwill ImpairmentLossRecognisedInProfitOrLossGoodwill GBP 4.00M 2019-01-01 2019-12-31 2019 FY 20-F 2020-03-06 0001193125-20-065064
ifrs-full ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill GBP 2.00M 2020-01-01 2020-12-31 2022 FY 20-F 2023-03-10 0001193125-23-067105
ifrs-full ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill GBP 888.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment GBP 193.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ImpairmentLossRecognisedInProfitOrLossRightofuseAssets ImpairmentLossRecognisedInProfitOrLossRightofuseAssets GBP 17.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss GBP 4.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncomeFromContinuingOperationsAttributableToOwnersOfParent IncomeFromContinuingOperationsAttributableToOwnersOfParent GBP 2.58B 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent IncomeFromDiscontinuedOperationsAttributableToOwnersOfParent GBP 0 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full IncomeTaxesPaidClassifiedAsOperatingActivities IncomeTaxesPaidClassifiedAsOperatingActivities GBP 1.20B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncomeTaxesPaidRefundClassifiedAsOperatingActivities IncomeTaxesPaidRefundClassifiedAsOperatingActivities GBP 1.20B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncomeTaxExpenseContinuingOperations IncomeTaxExpenseContinuingOperations GBP 1.11B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome GBP 2.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncomeTaxRelatingToFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome IncomeTaxRelatingToFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome GBP -47.00M 2017-01-01 2017-12-31 2019 FY 20-F 2020-03-06 0001193125-20-065064
ifrs-full IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome GBP 20.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome GBP 33.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges GBP -177.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination IncreaseDecreaseInContingentLiabilitiesRecognisedInBusinessCombination GBP -581.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset IncreaseDecreaseThroughBusinessCombinationsAndDisposalsNetDefinedBenefitLiabilityAsset GBP 0 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset GBP 321.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions IncreaseDecreaseThroughChangeInDiscountRateOtherProvisions GBP 24.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset GBP -11.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncreaseDecreaseThroughDisposalOfSubsidiary IncreaseDecreaseThroughDisposalOfSubsidiary GBP -2.00M 2024-01-01 2024-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities GBP 2.45B 2022-01-01 2022-12-31 2022 FY 20-F 2023-03-10 0001193125-23-067105
ifrs-full IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities GBP 5.67B 2022-01-01 2022-12-31 2022 FY 20-F 2023-03-10 0001193125-23-067105
ifrs-full IncreaseDecreaseThroughForeignExchangeFinancialAssets IncreaseDecreaseThroughForeignExchangeFinancialAssets GBP 3.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset GBP 79.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions GBP -83.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets GBP -17.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities GBP 301.00M 2022-01-01 2022-12-31 2022 FY 20-F 2023-03-10 0001193125-23-067105
ifrs-full IncreaseDecreaseThroughOtherDistributionsToOwners IncreaseDecreaseThroughOtherDistributionsToOwners GBP 15.53B 2022-01-01 2022-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full IncreaseDecreaseThroughSharebasedPaymentTransactions IncreaseDecreaseThroughSharebasedPaymentTransactions GBP 374.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions GBP 28.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncreaseDecreaseThroughTransfersAndOtherChangesEquity IncreaseDecreaseThroughTransfersAndOtherChangesEquity GBP -20.00M 2022-01-01 2022-12-31 2023 FY 20-F 2024-03-05 0001131399-24-000007
ifrs-full IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions GBP 7.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill GBP 48.00M 2021-01-01 2021-12-31 2021 FY 20-F 2022-03-08 0001193125-22-068957
ifrs-full IncreaseDecreaseThroughTransfersRightofuseAssets IncreaseDecreaseThroughTransfersRightofuseAssets GBP 6.00M 2023-01-01 2023-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full IntangibleAssetsOtherThanGoodwill IntangibleAssetsOtherThanGoodwill GBP 16.75B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full InterestExpense InterestExpense GBP 912.00M 2022-01-01 2022-12-31 2022 FY 20-F 2023-03-10 0001193125-23-067105
ifrs-full InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss GBP 612.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full InterestExpenseIncomeNetDefinedBenefitLiabilityAsset InterestExpenseIncomeNetDefinedBenefitLiabilityAsset GBP -4.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full InterestExpenseOnFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLoss InterestExpenseOnFinancialLiabilitiesDesignatedAtFairValueThroughProfitOrLoss GBP 0 2021-01-01 2021-12-31 2021 FY 20-F 2022-03-08 0001193125-22-068957
ifrs-full InterestExpenseOnLeaseLiabilities InterestExpenseOnLeaseLiabilities GBP 46.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost GBP 56.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full InterestIncomeOnAvailableforsaleFinancialAssets InterestIncomeOnAvailableforsaleFinancialAssets GBP 2.00M 2017-01-01 2017-12-31 2017 FY 20-F/A 2018-03-20 0001193125-18-088407
ifrs-full InterestIncomeOnCashAndCashEquivalents InterestIncomeOnCashAndCashEquivalents GBP 60.00M 2017-01-01 2017-12-31 2017 FY 20-F/A 2018-03-20 0001193125-18-088407
ifrs-full InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss GBP 91.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full InterestIncomeOnLoansAndReceivables InterestIncomeOnLoansAndReceivables GBP 1.00M 2017-01-01 2017-12-31 2017 FY 20-F/A 2018-03-20 0001193125-18-088407
ifrs-full InterestPaidClassifiedAsFinancingActivities InterestPaidClassifiedAsFinancingActivities GBP 679.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full InterestPayable InterestPayable GBP 52.00M 2017-12-31 2017 FY 20-F/A 2018-03-20 0001193125-18-088407
ifrs-full InterestReceivable InterestReceivable GBP 2.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full InterestReceivedClassifiedAsInvestingActivities InterestReceivedClassifiedAsInvestingActivities GBP 154.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full Inventories Inventories GBP 5.92B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full InventoryRecognisedAsOfAcquisitionDate InventoryRecognisedAsOfAcquisitionDate GBP 60.00M 2022-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full InventoryWritedown2011 InventoryWritedown2011 GBP 1.06B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full InvestmentAccountedForUsingEquityMethod InvestmentAccountedForUsingEquityMethod GBP 89.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full InvestmentsInSubsidiariesJointVenturesAndAssociates InvestmentsInSubsidiariesJointVenturesAndAssociates GBP 89.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod GBP 2.13B 2021-12-31 2021 FY 20-F 2022-03-08 0001193125-22-068957
ifrs-full IssuedCapital IssuedCapital GBP 1.35B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full IssueOfEquity IssueOfEquity GBP 15.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full KeyManagementPersonnelCompensation KeyManagementPersonnelCompensation GBP 81.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full KeyManagementPersonnelCompensationPostemploymentBenefits KeyManagementPersonnelCompensationPostemploymentBenefits GBP 2.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full KeyManagementPersonnelCompensationSharebasedPayment KeyManagementPersonnelCompensationSharebasedPayment GBP 39.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full KeyManagementPersonnelCompensationShorttermEmployeeBenefits KeyManagementPersonnelCompensationShorttermEmployeeBenefits GBP 34.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed GBP 2.00M 2019-01-01 2019 FY 20-F 2020-03-06 0001193125-20-065064
ifrs-full LeaseLiabilities LeaseLiabilities GBP 830.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full LegalProceedingsProvision LegalProceedingsProvision GBP 210.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full Liabilities Liabilities GBP 45.16B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full LiabilitiesArisingFromFinancingActivities LiabilitiesArisingFromFinancingActivities GBP 20.89B 2022-12-31 2022 FY 20-F 2023-03-10 0001193125-23-067105
ifrs-full LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale GBP 139.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full LiabilityAssetOfDefinedBenefitPlans LiabilityAssetOfDefinedBenefitPlans GBP -229.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full LongtermBorrowings LongtermBorrowings GBP 14.71B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full MaximumExposureToCreditRisk MaximumExposureToCreditRisk GBP 12.57B 2020-12-31 2020 FY 20-F 2021-03-12 0001193125-21-079417
ifrs-full MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease GBP 1.14B 2018-12-31 2018 FY 20-F 2019-03-15 0001193125-19-076716
ifrs-full MinimumOperatingLeasePayments MinimumOperatingLeasePayments GBP 188.00M 2018-01-01 2018-12-31 2018 FY 20-F 2019-03-15 0001193125-19-076716
ifrs-full MiscellaneousOtherOperatingIncome MiscellaneousOtherOperatingIncome GBP 237.00M 2023-01-01 2023-12-31 2023 FY 20-F 2024-03-05 0001131399-24-000007
ifrs-full NetAssetsLiabilities NetAssetsLiabilities GBP 15.96B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full NetDebt NetDebt GBP 14.45B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination GBP 280.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full NominalAmountOfHedgingInstrument NominalAmountOfHedgingInstrument pure 750.00M 2021-12-31 2021 FY 20-F 2022-03-08 0001193125-22-068957
ifrs-full NoncontrollingInterests NoncontrollingInterests GBP -421.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets GBP -83.00M 2022-12-31 2022 FY 20-F 2023-03-10 0001193125-23-067105
ifrs-full NoncurrentAssets NoncurrentAssets GBP 43.61B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale GBP 300.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners GBP 76.00M 2023-12-31 2023 FY 20-F 2024-03-05 0001131399-24-000007
ifrs-full NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts GBP 33.97B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full NoncurrentDeferredIncomeOtherThanNoncurrentContractLiabilities NoncurrentDeferredIncomeOtherThanNoncurrentContractLiabilities GBP 121.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full NoncurrentDerivativeFinancialAssets NoncurrentDerivativeFinancialAssets GBP 0 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full NoncurrentDerivativeFinancialLiabilities NoncurrentDerivativeFinancialLiabilities GBP 67.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full NoncurrentFinancialLiabilitiesAtFairValueThroughProfitOrLoss NoncurrentFinancialLiabilitiesAtFairValueThroughProfitOrLoss GBP 5.38B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod GBP 1.04B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full NoncurrentLeaseLiabilities NoncurrentLeaseLiabilities GBP 693.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full NoncurrentLiabilities NoncurrentLiabilities GBP 23.77B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full NoncurrentProvisionsForEmployeeBenefits NoncurrentProvisionsForEmployeeBenefits GBP 1.69B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full NoncurrentRecognisedAssetsDefinedBenefitPlan NoncurrentRecognisedAssetsDefinedBenefitPlan GBP 1.11B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full NumberOfSharesAuthorised NumberOfSharesAuthorised shares 10.00B 2018-12-31 2018 FY 20-F 2019-03-15 0001193125-19-076716
ifrs-full NumberOfSharesIssuedAndFullyPaid NumberOfSharesIssuedAndFullyPaid shares 4.32B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OnerousContractsProvision OnerousContractsProvision GBP 6.00M 2018-12-31 2018 FY 20-F 2019-03-15 0001193125-19-076716
ifrs-full OtherAdjustmentsToReconcileProfitLoss OtherAdjustmentsToReconcileProfitLoss GBP -9.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities GBP 92.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities GBP 4.00M 2020-01-01 2020-12-31 2020 FY 20-F 2021-03-12 0001193125-21-079417
ifrs-full OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities GBP 189.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities GBP 0 2023-01-01 2023-12-31 2023 FY 20-F 2024-03-05 0001131399-24-000007
ifrs-full OtherComprehensiveIncome OtherComprehensiveIncome GBP 493.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments GBP 215.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans GBP 133.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation GBP 213.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments GBP 215.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax GBP 216.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax GBP 277.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherCurrentFinancialAssets OtherCurrentFinancialAssets GBP 42.00M 2023-12-31 2023 FY 20-F 2024-03-05 0001131399-24-000007
ifrs-full OtherCurrentFinancialLiabilities OtherCurrentFinancialLiabilities GBP 1.05B 2023-12-31 2023 FY 20-F 2024-03-05 0001131399-24-000007
ifrs-full OtherCurrentPayables OtherCurrentPayables GBP 438.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherFinanceIncome OtherFinanceIncome GBP 7.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherFinanceIncomeCost OtherFinanceIncomeCost GBP -9.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherIncome OtherIncome GBP -7.00M 2018-01-01 2018-12-31 2018 FY 20-F 2019-03-15 0001193125-19-076716
ifrs-full OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates GBP -36.00M 2021-01-01 2021-12-31 2021 FY 20-F 2022-03-08 0001193125-22-068957
ifrs-full OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities GBP 46.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities GBP -11.00M 2023-01-01 2023-12-31 2023 FY 20-F 2024-03-05 0001131399-24-000007
ifrs-full OtherLongtermProvisions OtherLongtermProvisions GBP 610.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherMaterialNoncashItems OtherMaterialNoncashItems GBP 18.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherNoncurrentAssets OtherNoncurrentAssets GBP 2.15B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherNoncurrentFinancialLiabilities OtherNoncurrentFinancialLiabilities GBP 5.61B 2023-12-31 2023 FY 20-F 2024-03-05 0001131399-24-000007
ifrs-full OtherNoncurrentLiabilities OtherNoncurrentLiabilities GBP 1.02B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherNoncurrentPayables OtherNoncurrentPayables GBP 896.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherNoncurrentReceivables OtherNoncurrentReceivables GBP 80.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherOperatingIncomeExpense OtherOperatingIncomeExpense GBP 16.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherProvisions OtherProvisions GBP 1.55B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherReceivables OtherReceivables GBP 1.15B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherReserves OtherReserves GBP 1.32B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherShorttermProvisions OtherShorttermProvisions GBP 938.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherTangibleOrIntangibleAssetsTransferred OtherTangibleOrIntangibleAssetsTransferred GBP 6.00M 2019-12-31 2021 FY 20-F 2022-03-08 0001193125-22-068957
ifrs-full OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome GBP 33.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome pure 0.005 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ParValuePerShare ParValuePerShare GBP/shares 0.25 2018-12-31 2019 FY 20-F 2020-03-06 0001193125-20-065064
ifrs-full PastServiceCostNetDefinedBenefitLiabilityAsset PastServiceCostNetDefinedBenefitLiabilityAsset GBP 3.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full PaymentsFromChangesInOwnershipInterestsInSubsidiaries PaymentsFromChangesInOwnershipInterestsInSubsidiaries GBP 0 2021-01-01 2021-12-31 2021 FY 20-F 2022-03-08 0001193125-22-068957
ifrs-full PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities GBP 28.00M 2018-01-01 2018-12-31 2018 FY 20-F 2019-03-15 0001193125-19-076716
ifrs-full PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities GBP 241.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full PaymentsToAcquireOrRedeemEntitysShares PaymentsToAcquireOrRedeemEntitysShares GBP 1.38B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents GBP 5.00M 2022-01-01 2022-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full PostemploymentBenefitExpenseDefinedBenefitPlans PostemploymentBenefitExpenseDefinedBenefitPlans GBP 170.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full PostemploymentBenefitExpenseDefinedContributionPlans PostemploymentBenefitExpenseDefinedContributionPlans GBP 130.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full PostemploymentBenefitExpenseInProfitOrLoss PostemploymentBenefitExpenseInProfitOrLoss GBP 300.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full Prepayments Prepayments GBP 385.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ProceedsFromContributionsOfNoncontrollingInterests ProceedsFromContributionsOfNoncontrollingInterests GBP 0 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations GBP 104.00M 2019-01-01 2019-12-31 2021 FY 20-F 2022-03-08 0001193125-22-068957
ifrs-full ProceedsFromIssuingShares ProceedsFromIssuingShares GBP 15.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ProceedsFromNoncurrentBorrowings ProceedsFromNoncurrentBorrowings GBP 1.98B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities GBP 115.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ProceedsFromSalesOfInterestsInAssociates ProceedsFromSalesOfInterestsInAssociates GBP 3.00M 2018-01-01 2018-12-31 2020 FY 20-F 2021-03-12 0001193125-21-079417
ifrs-full ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod GBP 0 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities GBP 24.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ProfitLoss ProfitLoss GBP 6.29B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ProfitLossAttributableToNoncontrollingInterests ProfitLossAttributableToNoncontrollingInterests GBP 573.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ProfitLossAttributableToOwnersOfParent ProfitLossAttributableToOwnersOfParent GBP 5.72B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ProfitLossBeforeTax ProfitLossBeforeTax GBP 7.40B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ProfitLossFromContinuingOperations ProfitLossFromContinuingOperations GBP 2.95B 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests ProfitLossFromContinuingOperationsAttributableToNoncontrollingInterests GBP 376.00M 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full ProfitLossFromDiscontinuedOperations ProfitLossFromDiscontinuedOperations GBP 0 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests ProfitLossFromDiscontinuedOperationsAttributableToNoncontrollingInterests GBP 0 2024-01-01 2024-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full ProfitLossFromOperatingActivities ProfitLossFromOperatingActivities GBP 7.93B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ProfitLossOfAcquiree ProfitLossOfAcquiree GBP 0 2019-01-22 2019-12-31 2020 FY 20-F 2021-03-12 0001193125-21-079417
ifrs-full ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments GBP 0 2023-01-01 2023-12-31 2023 FY 20-F 2024-03-05 0001131399-24-000007
ifrs-full PropertyPlantAndEquipment PropertyPlantAndEquipment GBP 9.32B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate GBP 30.00M 2022-12-31 2024 FY 20-F 2025-03-03 0001131399-25-000007
ifrs-full Provisions Provisions GBP 0 2019-12-31 2019 FY 20-F 2020-03-06 0001193125-20-065064
ifrs-full ProvisionUsedOtherProvisions ProvisionUsedOtherProvisions GBP 1.65B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities GBP 1.64B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod GBP 0 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities GBP 1.35B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full PurchaseOfTreasuryShares PurchaseOfTreasuryShares GBP 1.38B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full RatedCreditExposures RatedCreditExposures GBP 5.14B 2016-12-31 2017 FY 20-F/A 2018-03-20 0001193125-18-088407
ifrs-full RawMaterialsAndConsumablesUsed RawMaterialsAndConsumablesUsed GBP 1.59B 2023-01-01 2023-12-31 2023 FY 20-F 2024-03-05 0001131399-24-000007
ifrs-full ReceivablesFromTaxesOtherThanIncomeTax ReceivablesFromTaxesOtherThanIncomeTax GBP 511.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ReclassificationAdjustmentsOnAvailableforsaleFinancialAssetsBeforeTax ReclassificationAdjustmentsOnAvailableforsaleFinancialAssetsBeforeTax GBP 42.00M 2017-01-01 2017-12-31 2019 FY 20-F 2020-03-06 0001193125-20-065064
ifrs-full ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax GBP -36.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax GBP -36.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax GBP 12.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full RepaymentsOfBondsNotesAndDebentures RepaymentsOfBondsNotesAndDebentures GBP 1.59B 2022-01-01 2022-12-31 2022 FY 20-F 2023-03-10 0001193125-23-067105
ifrs-full RepaymentsOfBorrowingsClassifiedAsFinancingActivities RepaymentsOfBorrowingsClassifiedAsFinancingActivities GBP 2.50B 2019-11-30 2020 FY 20-F 2021-03-12 0001193125-21-079417
ifrs-full RepaymentsOfCurrentBorrowings RepaymentsOfCurrentBorrowings GBP 2.12B 2023-01-01 2023-12-31 2023 FY 20-F 2024-03-05 0001131399-24-000007
ifrs-full RepaymentsOfNoncurrentBorrowings RepaymentsOfNoncurrentBorrowings GBP 1.40B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ResearchAndDevelopmentExpense ResearchAndDevelopmentExpense GBP 7.53B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ReserveOfExchangeDifferencesOnTranslation ReserveOfExchangeDifferencesOnTranslation GBP -894.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full RetainedEarnings RetainedEarnings GBP 10.21B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset GBP 98.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full Revenue Revenue GBP 32.67B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full RevenueAndOperatingIncome RevenueAndOperatingIncome GBP 127.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods GBP 1.75B 2023-01-01 2023-12-31 2023 FY 20-F 2024-03-05 0001131399-24-000007
ifrs-full RevenueFromRenderingOfServices RevenueFromRenderingOfServices GBP 7.00M 2021-01-01 2021-12-31 2021 FY 20-F 2022-03-08 0001193125-22-068957
ifrs-full RevenueFromRoyalties RevenueFromRoyalties GBP 879.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full RevenueFromSaleOfGoods RevenueFromSaleOfGoods GBP 32.67B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ReversalOfImpairmentLossRecognisedInProfitOrLoss ReversalOfImpairmentLossRecognisedInProfitOrLoss GBP 16.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment GBP 33.00M 2017-01-01 2017-12-31 2017 FY 20-F/A 2018-03-20 0001193125-18-088407
ifrs-full ReversalOfImpairmentLossRecognisedInProfitOrLossRightofuseAssets ReversalOfImpairmentLossRecognisedInProfitOrLossRightofuseAssets GBP 1.00M 2024-01-01 2024-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ReversalOfInventoryWritedown ReversalOfInventoryWritedown GBP 575.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ReversalOfProvisionsForCostOfRestructuring ReversalOfProvisionsForCostOfRestructuring GBP 111.00M 2022-01-01 2022-12-31 2022 FY 20-F 2023-03-10 0001193125-23-067105
ifrs-full RightofuseAssets RightofuseAssets GBP 726.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full RightofuseAssetsIncreaseDecreaseInRevaluationSurplus RightofuseAssetsIncreaseDecreaseInRevaluationSurplus GBP -2.00M 2020-01-01 2020-12-31 2021 FY 20-F 2022-03-08 0001193125-22-068957
ifrs-full SellingGeneralAndAdministrativeExpense SellingGeneralAndAdministrativeExpense GBP 9.09B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax GBP -77.00M 2015-01-01 2015-12-31 2017 FY 20-F/A 2018-03-20 0001193125-18-088407
ifrs-full ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod GBP 1.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full SharePremium SharePremium GBP 3.50B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ShorttermBorrowings ShorttermBorrowings GBP 3.01B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full ShorttermDepositsClassifiedAsCashEquivalents ShorttermDepositsClassifiedAsCashEquivalents GBP 2.84B 2022-12-31 2022 FY 20-F 2023-03-10 0001193125-23-067105
ifrs-full ShorttermLegalProceedingsProvision ShorttermLegalProceedingsProvision GBP 189.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full SocialSecurityContributions SocialSecurityContributions GBP 865.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full SubleasePaymentsRecognisedAsExpense SubleasePaymentsRecognisedAsExpense GBP 5.00M 2018-01-01 2018-12-31 2018 FY 20-F 2019-03-15 0001193125-19-076716
ifrs-full TaxEffectFromChangeInTaxRate TaxEffectFromChangeInTaxRate GBP 35.00M 2017-01-01 2017-12-31 2017 FY 20-F/A 2018-03-20 0001193125-18-088407
ifrs-full TaxEffectOfForeignTaxRates TaxEffectOfForeignTaxRates GBP -20.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full TaxExpenseIncomeAtApplicableTaxRate TaxExpenseIncomeAtApplicableTaxRate GBP 1.07B 2022-01-01 2022-12-31 2022 FY 20-F 2023-03-10 0001193125-23-067105
ifrs-full TaxRateEffectFromChangeInTaxRate TaxRateEffectFromChangeInTaxRate pure 0.01 2017-01-01 2017-12-31 2017 FY 20-F/A 2018-03-20 0001193125-18-088407
ifrs-full TaxRateEffectOfForeignTaxRates TaxRateEffectOfForeignTaxRates pure -0.003 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full TaxRateEffectOfTaxLosses TaxRateEffectOfTaxLosses pure 0.005 2018-01-01 2018-12-31 2018 FY 20-F 2019-03-15 0001193125-19-076716
ifrs-full TerminationBenefitsExpense TerminationBenefitsExpense GBP 374.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full TradeAndOtherCurrentPayables TradeAndOtherCurrentPayables GBP 15.38B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full TradeAndOtherCurrentReceivables TradeAndOtherCurrentReceivables GBP 7.47B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full TradeAndOtherPayablesRecognisedAsOfAcquisitionDate TradeAndOtherPayablesRecognisedAsOfAcquisitionDate GBP 39.00M 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full TradeAndOtherPayablesToTradeSuppliers TradeAndOtherPayablesToTradeSuppliers GBP 3.54B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full TradeAndOtherReceivables TradeAndOtherReceivables GBP 7.47B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full TradeReceivables TradeReceivables GBP 5.91B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full TreasuryShares TreasuryShares GBP 3.95B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full UnusedProvisionReversedOtherProvisions UnusedProvisionReversedOtherProvisions GBP 148.00M 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised GBP 5.00M 2021-12-31 2021 FY 20-F 2022-03-08 0001193125-22-068957
ifrs-full WagesAndSalaries WagesAndSalaries GBP 6.84B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16 WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16 pure 0.031 2019-01-01 2019 FY 20-F 2020-03-06 0001193125-20-065064
ifrs-full WeightedAverageShares WeightedAverageShares shares 4.05B 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full WorkInProgress WorkInProgress GBP 3.70B 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004
ifrs-full WritedownsReversalsOfPropertyPlantAndEquipment WritedownsReversalsOfPropertyPlantAndEquipment GBP 3.00M 2020-01-01 2020-12-31 2020 FY 20-F 2021-03-12 0001193125-21-079417
srt CommercialPaperAverageRatePaid CommercialPaperAverageRatePaid pure 0.038 2025-01-01 2025-12-31 2025 FY 20-F 2026-03-06 0001131399-26-000004

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →